Natera, Inc. (NTRA) is an Austin, Texas–based molecular diagnostics company whose cell-free DNA platform powers Signatera, a personalized blood test that detects residual cancer DNA after treatment, along with Panorama prenatal screening and Prospera organ-transplant rejection monitoring. In Thursday's session, the stock traded at $296.43, up 2.39% from the previous close of $289.50, confirming an upward move. No verified company-specific catalyst was identified for the advance; the gain instead reflects buyers stepping into a name that had fallen more than 30% from its late-October peak, with support from relative strength in diagnostics peers.
No verified news or fundamental catalyst found in Thursday's flow. There was no earnings report, guidance update, regulatory decision, financing, or new sell-side action tied to the session. The most likely explanation is technical: a rebound attempt in an oversold large cap after a sharp post-earnings repricing. NTRA fell 14.59% on Nov. 6, the session after third-quarter results, and another 9.59% on Nov. 16, a cumulative decline of more than 20% in eight sessions. Shares have now stabilized across three consecutive sessions, closing at $287.47, then $289.50, and trading higher again Thursday. That pattern is consistent with dip-buying and short-term position resetting rather than a reassessment of fundamentals.
The two overhangs that drove the November decline are both being re-examined by investors. First, the Centers for Medicare & Medicaid Services published its proposed CRUSH anti-fraud rule on Nov. 16, and the 545-page proposal contains no dedicated laboratory or molecular diagnostics provisions — a relief for a group that had feared new registration requirements for proprietary tests. Second, the company's immediate CEO transition, with Solomon Moshkevich succeeding Steve Chapman, has been repeatedly framed by management as continuity; the CFO has publicly defended the abrupt handoff and reiterated the $6 billion 2029 revenue target. Neither item is new Thursday, but both reduce the probability of further forced selling.
The move was idiosyncratic rather than sector-wide. Guardant Health rose about 2.9% and Veracyte gained roughly 1.8%, while GeneDx and Illumina traded lower. The divergence suggests money is rotating selectively toward precision-diagnostics names with differentiated oncology franchises rather than buying the group indiscriminately — a pattern that favors NTRA given Signatera's position as the most widely adopted molecular residual disease test in the United States.
Volume was unremarkable: roughly 630,000 shares had changed hands by midday against an average daily volume near 1.7 million, implying a pace broadly in line with normal activity. That lack of volume confirmation argues against reading Thursday's gain as institutional accumulation. The stock opened higher near $294.75, reached an intraday high of $307.19, and then pared the advance, which itself signals that sellers remain active above $300. The move ran directly against the broader market, with the S&P 500 and Nasdaq-100 each down about 0.9% and the health care sector ETF off roughly 1.7%. Technically, the shares remain well below their 50-day moving average and roughly 32% under the 52-week closing high of $436.00, with the mid-$270s — the low of the Nov. 16–18 sessions — emerging as the nearest support level.
The score runs from 0, meaning no meaningful news and a move entirely normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This session earns a 10 out of 100. There was no verified company news at all, only the ongoing digestion of announcements already made earlier in November, which is weak by any materiality standard for a company with a market capitalization above $40 billion. The price move was equally unremarkable: at 2.39%, it was just over one times the stock's average absolute daily change of 2.33% across the past 60 sessions, and moves of that size or larger occurred 23 times in that window. Two modest components combine into a low score.
Fourth-quarter and full-year 2026 results are expected in late February 2027, and investors will focus on two metrics: clinical Signatera unit growth, which reached roughly 316,000 in the third quarter, and the operating margin, which narrowed sharply on a trailing basis but still sits in negative territory. Management has guided full-year revenue to $3.005–$3.035 billion and targets $6 billion by 2029. Near-term catalysts include nine to ten pending MolDx submissions for additional cancer types, the Signatera launch in Japan, broader adoption of the Signatera Genome assay, and a 2027 readout from the 30,000-patient FIND colorectal screening study. Risks include gross-margin dilution from newer products, competitive entry into tumor-informed MRD testing, reimbursement timing, and the execution risk inherent in a first-year CEO. Valuation near 14 times trailing sales leaves little room for disappointment.
Tickeron operates hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the page functions as a live screen of what is currently working rather than a static list. Investors looking to pair fundamental research with systematic signals can review the current leaders.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day moving average for NTRA crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 66 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 30 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.
NTRA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for NTRA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.585) is normal, around the industry mean (67.298). NTRA's P/E Ratio (-230.126) is considerably lower than the industry average of (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. NTRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a genetic testing company which develops proprietary bioinformatics-based technology
Industry MedicalSpecialties